TY - JOUR
T1 - Chronic GVHD risk score
T2 - A Center for International Blood and Marrow Transplant Research analysis
AU - Arora, Mukta
AU - Klein, John P.
AU - Weisdorf, Daniel J.
AU - Hassebroek, Anna
AU - Flowers, Mary E.D.
AU - Cutler, Corey S.
AU - Urbano-Ispizua, Alvaro
AU - Antin, Joseph H.
AU - Bolwell, Brian J.
AU - Boyiadzis, Michael
AU - Cahn, Jean Yves
AU - Cairo, Mitchell S.
AU - Isola, Luis
AU - Jacobsohn, David A.
AU - Jagasia, Madan
AU - Klumpp, Thomas R.
AU - Lee, Stephanie J.
AU - Petersdorf, Effie W.
AU - Santarone, Stella
AU - Gale, Robert Peter
AU - Schouten, Harry C.
AU - Spellman, Stephen
AU - Wingard, John R.
AU - Horowitz, Mary M.
AU - Pavletic, Steven Z.
PY - 2011/6/16
Y1 - 2011/6/16
N2 - Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
AB - Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
UR - https://www.scopus.com/pages/publications/79959193801
U2 - 10.1182/blood-2010-12-323824
DO - 10.1182/blood-2010-12-323824
M3 - Article
C2 - 21493797
AN - SCOPUS:79959193801
SN - 0006-4971
VL - 117
SP - 6714
EP - 6720
JO - Blood
JF - Blood
IS - 24
ER -